SCHEMBL20051881

SCHEMBL20051881

C[C@@H](OC(=O)C(=O)N1CCCCC1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HPGD P15428 3/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
POLB P06746 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19500259 0.83 SMN1; SMN2 (0.45) ALDH1A1MAPTRAB9ASMN1; SMN2CYP3A4
SCHEMBL20051886 0.81 SMN1; SMN2 (0.42) ALDH1A1HPGDNPC1MAPTHTT
SCHEMBL14752957 0.76 SMN1; SMN2 (0.37) ALDH1A1HPGDNPC1MAPTHTT
SCHEMBL19500256 0.71 KMT2A (0.41) HPGDMEN1KMT2ANPSR1
SCHEMBL6039784 0.71 HPGD (0.46) ALDH1A1HPGDNPC1MAPTHTT
SCHEMBL19500257 0.69 KMT2A (0.40) HPGDMEN1KMT2ACYP1A2NPSR1
SCHEMBL31308990 0.68 TSHR (0.31) MMP1MMP2MMP3MMP9
SCHEMBL261394 0.68 SMN1; SMN2 (0.43) ALDH1A1HPGDNPC1MAPTRAB9A
SCHEMBL20585124 0.67 ALDH1A1 (0.41) ALDH1A1HPGDNPC1MAPTHTT
SCHEMBL6039893 0.67 HPGD (0.42) ALDH1A1HPGDMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186808-A1 NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC 2018-07-05 US disclosed
US-9944654-B2 Nargenicin compounds and uses thereof as antibacterial agents MERCK SHARP & DOHME CORP. (US) 2018-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186808-A1 NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS NRDC, MME, NME2 ALDH1A1 2012/4885HPGD 370/4885NPC1 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.